View Filing Data

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2017	Nov. 01, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q3
Entity Registrant Name	TAPIMMUNE INC.
Entity Central Index Key	0001094038
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	TPIV
Entity Common Stock, Shares Outstanding		10,539,057

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash	$ 7,607,735	$ 7,851,243
Prepaid expenses and deposits	96,530	70,149
Total current assets	7,704,265	7,921,392
Total assets	7,704,265	7,921,392
Current liabilities:
Accounts payable and accrued liabilities	1,757,062	1,224,940
Research agreement obligations	0	492,365
Warrant liability	6,000	14,500
Promissory note	5,000	5,000
Total current liabilities	1,768,062	1,736,805
Total liabilities	1,768,062	1,736,805
COMMITMENTS AND CONTINGENCIES
Stockholders' equity:
Common stock, $0.001 par value, 41.7 million shares authorized, 10.5 million and 8.4 million shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively	10,539	8,421
Additional paid-in capital	160,662,286	151,991,974
Accumulated deficit	(154,736,622)	(145,815,808)
Total stockholders' equity	5,936,203	6,184,587
Total liabilities and stockholders' equity	7,704,265	7,921,392
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value	0	0
Series B Preferred Stock [Member]
Stockholders' equity:
Preferred Stock, Value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	5,000,000	5,000,000
Common stock shares par value	$ 0.001	$ 0.001
Common stock shares authorized	41,700,000	41,700,000
Common stock shares issued	10,500,000	8,400,000
Common stock shares outstanding	10,500,000	8,400,000
Series A Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,250,000	1,250,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Series B Preferred Stock [Member]
Preferred stock par value	$ 0.001	$ 0.001
Preferred stock shares authorized/designated	1,500,000	1,500,000
Preferred stock issued	0	0
Preferred stock outstanding	0	0

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Operating expenses:
Research and development	$ 1,623,302	$ 1,109,332	$ 3,815,119	$ 3,343,248
General and administrative	2,549,272	1,612,305	5,167,582	3,557,701
Total operating expenses	4,172,574	2,721,637	8,982,701	6,900,949
Loss from operations	(4,172,574)	(2,721,637)	(8,982,701)	(6,900,949)
Other income (expense):
Change in fair value of warrant liabilities	4,000	684,000	8,500	5,925,000
Debt extinguishment gain	0	0	492,365	0
Grant income	183,064	0	183,064	231,200
Loss on debt settlement agreements	0	(65,325)	0	(135,640)
Other income	0	0	0	1,828
Net loss	$ (3,985,510)	$ (2,102,962)	$ (8,298,772)	$ (878,561)
Basic net loss per share	$ (0.39)	$ (0.29)	$ (0.91)	$ (0.14)
Diluted net loss per share	$ (0.39)	$ (0.29)	$ (0.91)	$ (0.54)
Weighted average number of common shares outstanding, basic	10,219,138	7,281,000	9,081,678	6,370,000
Weighted average number of common shares outstanding, diluted	10,219,138	7,281,000	9,081,678	6,935,000

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - 9 months ended Sep. 30, 2017 - USD ($)	Total	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]
Balance, Amount at Dec. 31, 2016	$ 6,184,587	$ 8,421	$ 151,991,974	$ (145,815,808)
Balance, Share at Dec. 31, 2016		8,421,185
Common stock and warrants issued in private placement, Amount	6,190,003	$ 1,504	6,188,499	0
Common stock and warrants issued in private placement, Share		1,503,567
Fees and legal costs relating to private placement	(781,660)	$ 0	(781,660)	0
Exercise of warrants, Amount	666,666	$ 168	666,498	0
Exercise of warrants, Share		167,926
Legal costs relating to exercise of warrants	(47,043)	$ 0	(47,043)	0
Fair value of repriced warrants as inducement	0	0	622,042	(622,042)
Stock-based compensation, Amount	2,332,915	$ 544	2,332,371	0
Stock-based compensation, Share		544,018
Repurchase of common stock to pay for employee withholding taxes	(310,493)	$ (98)	(310,395)	0
Repurchase of common stock to pay for employee withholding taxes, Share		(97,639)
Net loss	(8,298,772)	$ 0	0	(8,298,772)
Balance, Amount at Sep. 30, 2017	$ 5,936,203	$ 10,539	$ 160,662,286	$ (154,736,622)
Balance, Share at Sep. 30, 2017		10,539,057

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash Flows from Operating Activities:
Net loss	$ (8,298,772)	$ (878,561)
Reconciliation of net loss to net cash used in operating activities:
Changes in fair value of warrant liabilities	(8,500)	(5,925,000)
Shares issued in debt settlement agreements	0	70,315
Stock-based compensation	2,332,915	1,309,109
Debt extinguishment gain	(492,365)	0
Changes in operating assets and liabilities:
Prepaid expenses and deposits	(26,381)	(42,849)
Accounts payable and accrued expenses	532,122	710,720
Net cash used in operating activities	(5,960,981)	(4,756,266)
Cash Flows from Financing Activities:
Proceeds from issuance of common stock and warrants in private placement, net of offering costs	5,408,343	2,331,126
Proceeds from exercise of stock warrants, net of offering costs	619,623	5,483,349
Repayment of promissory note	0	(25,000)
Repayment of promissory note - related party	0	(23,000)
Repurchase of common stock to pay for employee withholding taxes	(310,493)	0
Net cash provided by financing activities	5,717,473	7,766,475
Net (decrease) increase in cash	(243,508)	3,010,209
Cash at beginning of period	7,851,243	6,576,564
Cash at end of period	7,607,735	9,586,773
Supplemental schedule of non-cash financing activities:
Fair value of repriced warrants as inducement	622,042	0
Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson’s compensation	0	191,000
Fair value of issuance of series F and F-1 warrants as inducement in August 2016	0	5,352,000
Fair value of shares issued as inducement on August 10, 2016	0	4,500,000
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements	0	15,465,000
Reclassification of Derivative Warrant Liabilities to Equity at Exercise Date	$ 0	$ 5,074,000

NATURE OF OPERATIONS

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

Note 1: Nature of Operations

TapImmune Inc. (the “Company” or “we”), a Nevada corporation incorporated in 1992, is a biotechnology company focusing on immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. Unlike other vaccine technologies that narrowly address the initiation of an immune response, TapImmune's approach broadly stimulates the cellular immune system by enhancing the function of killer T-cells and T-helper cells and by restoring antigen presentation in tumor cells allowing their recognition and killing by the immune system.

BASIS OF PRESENTATION

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION

NOTE 2: Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the Company prepares its annual audited consolidated financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of such interim results.

The results for the condensed consolidated statement of operations are not necessarily indicative of results to be expected for the year ending December 31, 2017 or for any future interim period. The condensed consolidated balance sheet at September 30, 2017 has been derived from unaudited financial statements; however, it does not include all of the information and notes required by U.S. GAAP for complete financial statements. The accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements for the year ended December 31, 2016, and notes thereto included in the Company’s annual report on Form 10-K filed on March 14, 2017.

LIQUIDITY AND FINANCIAL CONDITION

9 Months Ended

Sep. 30, 2017

Text Block [Abstract]

LIQUIDITY AND FINANCIAL CONDITION

NOTE 3: LIQUIDITY AND FINANCIAL CONDITION

The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances and collaborations. From inception, the Company has been funded by a combination of equity and debt financings and warrant exercises.

The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.

As of September 30, 2017, the Company had cash of $7.6 million. The Company had net losses and negative cash flows from operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. Our financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Note 4: SIGNIFICANT ACCOUNTING POLICIES

There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the Company’s annual report on Form 10-K, which was filed with the SEC on March 14, 2017.

New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed, we do not believe that the impact of recently issued standards that are not yet effective will have a material impact on our financial position or results of operations upon adoption.

Accounting for Certain Financial Instruments with Down Round Features

On July 13, 2017, the FASB has issued a two-part Accounting Standards Update (“ASU”), No. 2017-11, (i). Accounting for Certain Financial Instruments with Down Round Features and (ii) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception.

The ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018 and the interim periods within that annual period. Early adoption is permitted. The Company is evaluating the impact of adopting this standard on the consolidated financial statements and disclosures.

Compensation-Stock Compensation

In May 2017, the FASB issued ASU No. 2017-09, Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting, which clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award (as equity or liability) changes as a result of the change in terms or conditions. It is effective prospectively for the annual period beginning after December 15, 2017 and interim periods within that annual period. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on the consolidated financial statements and disclosures, but does not expect it to have a significant impact.

NET LOSS PER SHARE

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

NET INCOME (LOSS) PER SHARE

Note 5: NET LOSS PER SHARE

Basic loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted loss per common share is computed similar to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

The following table sets forth the computation of net loss per share:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Numerator:
Net loss	$	(3,985,510)	$	(2,102,962)	$	(8,298,772)	$	(878,561)
Less: non-cash income from change in fair value of common stock warrants		-		-		-		2,856,000
Net loss - diluted		(3,985,510)		(2,102,962)		(8,298,772)		(3,734,561)

Denominator:
Weighted average common shares outstanding - basic		10,219,138		7,281,000		9,081,678		6,370,000
Dilutive effect of warrants, net		-		-		-		565,000
Weighted average common shares outstanding - diluted		10,219,138		7,281,000		9,081,678		6,935,000

Net loss per share data:
Basic	$	(0.39)	$	(0.29)	$	(0.91)	$	(0.14)
Diluted	$	(0.39)	$	(0.29)	$	(0.91)	$	(0.54)

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	Nine Months Ended
	September 30,
	2017		2016
Common stock options		455,000		432,000
Common stock warrants - equity treatment		6,517,500		5,054,000
Common stock warrants - liability treatment		3,500		6,000
Potentially dilutive securities		6,976,000		5,492,000

RESEARCH AGREEMENT OBLIGATIONS

9 Months Ended

Sep. 30, 2017

Research and Development [Abstract]

RESEARCH AGREEMENT OBLIGATIONS

Note 6: Research Agreement OBLIGATIONS

Crucell Holland B. V. (“Crucell”) – Research License and Option Agreement

In 2003 and further amended in 2008, the Company acquired a research license and option agreement from Crucell Holland B.V. for use of an adenovirus technology. The Company has not made use of the technology in its current work and has not asked for nor received any work product from Crucell. Crucell was acquired by Johnson and Johnson in 2010.

As of December 31, 2016, the Company had accrued $0.5 million under the amended agreement.

Upon further third-party Netherlands legal review and analysis of the agreement undertaken during the year, it was concluded that based upon Dutch law, the statute of limitations has run out on the obligation, and a legal opinion received by the Company confirms the amounts are not currently owed. As such, as of September 30, 2017, the Company was no longer obligated to make the payments under the agreement and therefore, the Company recorded a debt extinguishment gain of $0.5 million and reduced the liability amount owed to $0 during the nine-month period ended September 30, 2017.

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2017

Derivatives and Fair Value [Abstract]

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS

Note 7: WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS

A summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are categorized within Level 3 of the fair value hierarchy at September 30, 2017 and December 31, 2016 is as follows:

	September 30,			December 31,
	2017			2016
Stock price	$	3.01		$	3.88
Exercise price	$	1.20		$	1.20
Contractual term (years)		0.78			1.15
Volatility (annual)		63	%		100	%
Risk-free rate		1	%		1	%
Dividend yield (per share)		0	%		0	%

The foregoing assumptions are reviewed quarterly and are subject to change based primarily on management’s assessment of the probability of the events described occurring. Accordingly, changes to these assessments could materially affect the valuations.

Financial Liabilities Measured at Fair Value on a Recurring Basis

Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:

Fair value measured at September 30, 2017

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

September 30, 2017

Warrant liability

6,000

Fair value measured at December 31, 2016

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2016

Warrant liability

14,500

The fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:

Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;

Level 2 inputs: Inputs, other than quoted prices included in Level 1, that are observable either directly or indirectly; and

Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.

There were no transfers between Level 1, 2 or 3 during the nine months ended September 30, 2017.

The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2017:

	Warrant
	Liability
Balance - December 31, 2016	$	14,500
Change in fair value of warrant liability		(8,500)
Balance – September 30, 2017	$	6,000

PROMISSORY NOTE

9 Months Ended

Sep. 30, 2017

Promissory Notes [Abstract]

PROMISSORY NOTES

Note 8: Promissory note

At September 30, 2017 and December 31, 2016, the Company had an outstanding promissory note in the amount of $5,000. The promissory note outstanding and due at September 30, 2017 bears 10% annual interest.

STOCKHOLDERS’ EQUITY

9 Months Ended

Sep. 30, 2017

Stockholders' Equity Note [Abstract]

STOCKHOLDERS’ EQUITY

Note 9: STOCKHOLDERS’ EQUITY

2017 Common Stock Transactions

June 2017 Private Placement Transaction

On June 26, 2017, the Company completed private placement of units with certain accredited investors. In the private placement transaction, the Company sold 1,503,567 shares of common stock for $3.97 per share and five-year warrants to purchase an equal number of shares of common stock, at an exercise price of $3.97 per share, for $0.125 per warrant, with one common share and one warrant being sold together as a unit for a total of $4.095 per unit. The Company issued and sold an aggregate of 1,503,567 million units for aggregate gross proceeds of $6.2 million. The Company incurred $0.8 million in agency fees and legal costs. In connection with the offering, the Company reduced the exercise price for the warrants to purchase an aggregate of 653,187 shares of common stock issued to investors in the private placement that closed in August 2016 from $6.00 per share to $3.97 per share.

In addition, the Company issued five-year warrants to the placement agent in the offering providing for the purchase of up to 150,357 shares of Company common stock for $3.97 per share.

Pursuant to a Registration Rights Agreement to be entered into at the closing of the private placement offering, promptly, but no later than 90 calendar days after the closing of the offering, the Company is required to file a registration statement with the Securities and Exchange Commission registering for resale (a) the common stock issued in the offering; (b) the shares of common stock issuable upon the exercise of the private placement warrants; and (c) the shares of common stock issuable upon the exercise of the warrants issued to Katalyst Securities LLC, which acted as placement agent for the offering. The Company is required to use its commercially reasonable efforts to ensure that the Registration Statement is declared effective within 90 calendar days after filing with the Securities and Exchange Commission, on or before December 23, 2017.

In accordance with the registration rights agreements, should the Company fail to meet the above criteria, the Company is subject to pay the investors liquidated damages. The liquidated damages shall be a cash sum payment calculated at a rate of ten percent (10%) per annum of the aggregate purchase price for the registrable securities or aggregate amount upon exercise of the placement agent warrants.

In accordance with U.S. GAAP, a contingent obligation to make future payments must be recorded if the transfer of consideration under a registration payment arrangement is probable and can be reasonably estimated. The Company has determined that should it be required to pay liquidated damages to the investors of the private placements, the aggregate contingent liability it would be required to record would be approximately $57,000 per month for each month it fails or is estimated to fail to meet the above criteria.

At the June 26, 2017 private placement closing, and on September 30, 2017, the Company concluded that it is not probable that it will be required to remit any payments to the investors for failing to obtain an effective registration statement or failing to maintain its effectiveness.

June 2017 Exercise and Repricing of Warrants Held by Existing Institutional Investors

On June 23, 2017, certain existing institutional shareholders of the Company who hold various outstanding warrants (i.e. C, D, E and F) to purchase Company common stock, entered into warrant repricing and exercise agreements.

Series E repriced and exercised warrants

Approximately 168,000 of Series E warrants were repriced from $15.00 per share to $3.97 per share and exercised immediately for gross proceeds of approximately $0.7 million. Series E warrants to purchase approximately 187,000 shares of Company common stock being reduced from $15.00 per share to $4.50 per share.

Series C, D & F repriced warrants

Additionally, the exercise prices for certain investors of Series C, Series D and Series F warrants were reduced as follows:

	Number of
	Warrant Shares		Pre-reduced		Post-reduced
Series	Repriced		Price		Price
Series C		313,750	$	6.00	$	4.00
Series D		312,500	$	9.00	$	4.00
Series F		292,500	$	7.20	$	4.00

The fair value relating to the modification of exercise prices on the repriced warrants was treated as deemed dividend on the statement of stockholders’ equity of $0.6 million.

A weighted average summary of quantitative information with respect to valuation methodology and significant unobservable inputs used for the Company’s common stock purchase warrants that are included in the modification is as follows:

	Before			After
	Modification			Modification
Exercise price	$	8.32		$	4.04
Contractual term (years)		3.34			3.34
Volatility (annual)		200	%		200	%
Risk-free rate		2	%		2	%
Dividend yield (per share)		0	%		0	%

2017 Management Compensation

On March 9, 2017, the Company issued 12,761 shares of stock in relation to the discretionary 2016 bonus awarded to Dr. Glynn Wilson. The fair value of the common stock of $55,000 was recognized as stock-based compensation in general and administrative expenses. The issuance was based on the closing price or our common stock of $4.31 per share, on the day immediately preceding the date the 2016 bonus award was approved by the Board of Directors.

On March 9, 2017, the Company issued 5,220 shares of stock in relation to the discretionary 2016 bonus awarded to our former Chief Operating Officer. The fair value of the common stock of $22,500 was recognized as stock-based compensation in general and administrative expenses. The issuance was based on the closing price or our common stock of $4.31 per share, on the day immediately preceding the date the 2016 bonus award was approved by the Board of Directors.

On September 22, 2017, the Company entered into an employment agreement with Peter Hoang, the Company’s Chief Executive Officer. As part of the agreement, the Company granted Mr. Hoang 250,000 shares of unregistered, fully vested restricted common stock. The Company recorded $0.8 million of stock-based compensation based on the fair value of the common stock at September 22, 2017. 70,289 shares of common stock, with a fair value of $0.2 million, were withheld (at the closing price of the Company's common stock on the NASDAQ Capital Market on September 22, 2017) to satisfy certain payroll liabilities, as applicable to the award.

On September 22, 2017, the Company entered into an amended employment agreement with Dr. Glynn Wilson, the Company’s continuing Chairman to serve as the Company’s Strategic Advisor. As part of the agreement, the Company granted Dr. Wilson 100,000 shares of unregistered, fully vested restricted common stock. The Company recorded $0.3 million of stock-based compensation based on the fair value of the common stock at September 22, 2017. 27,350 shares of common stock, with a fair value of $0.1 million, were withheld (at the closing price of the Company's common stock on the NASDAQ Capital Market on September 22, 2017) to satisfy certain payroll liabilities, as applicable to the award.

Consulting Arrangements

During the nine months ended September 30, 2017, the Company issued 0.1 million shares of common stock as part of consulting agreements. The fair value of the common stock of $0.4 million was recognized as stock-based compensation in general and administrative expenses.

STOCK-BASED COMPENSATION

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

Note 10: STOCK-BASED COMPENSATION

The Company recorded $1.7 million and $0.8 million of stock-based compensation expense for the three months ended September 30, 2017 and 2016, respectively. The Company recorded $2.3 million and $1.3 million of stock-based compensation expense for the nine months ended September 30, 2017 and 2016, respectively. Stock-based compensation expense is included in general and administrative expense on the condensed consolidated statements of operations.

At September 30, 2017, the total stock-based compensation cost related to unvested awards not yet recognized was $0.5 million. The expected weighted average period compensation costs to be recognized was 0.62 years.

Future option grants will impact the compensation expense recognized.

GRANT INCOME

9 Months Ended

Sep. 30, 2017

Text Block [Abstract]

GRANT INCOME

Note 11: GRANT INCOME

During the nine months ended September 30, 2017 and September 30, 2016, the Company received $0.2 million of a grant awarded to Mayo Foundation from the U.S. Department of Defense for the Phase II Clinical Trial of TPIV200. The grant compensated the Company for clinical supplies manufactured and provided by the Company for the clinical study.

CONTINGENCIES AND COMMITMENTS

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

CONTINGENCIES AND COMMITMENTS

Note 12: CONTINGENCIES AND COMMITMENTS

Employment Agreements

On September 22, 2017, the Company appointed Peter Hoang as the Company’s President and Chief Executive Officer. In connection with Mr. Hoang’s appointment, he entered into an employment agreement with the Company. The employment agreement provides that Mr. Hoang’s base salary will be $362,500 per year and he is eligible for an annual performance bonus of up to 50% of his base salary. In addition, on the first anniversary of the employment agreement, Mr. Hoang will be eligible to receive a grant of stock options to purchase the number of shares of common stock equal to one percent of the then-outstanding common stock of the Company. The term of the employment agreement is for three years and will be automatically extended for an additional 12 months unless terminated by Mr. Hoang or the Company.

On September 22, 2017, the Company entered into an amended employment agreement with Dr. Glynn Wilson, the Company’s Strategic Advisor. The amended employment agreement provides that Dr. Wilson’s base salary will be $205,000 per year and he is eligible for an annual performance bonus of up to 50% of his base salary. In addition, upon the first anniversary of the execution of amendment employment agreement, Dr. Wilson will be eligible to receive an additional grant of restricted common stock equal to $300,000. The term of the employment agreement is through December 31, 2018.

SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

New Accounting Pronouncements

New Accounting Pronouncements

Accounting for Certain Financial Instruments with Down Round Features

Compensation-Stock Compensation

NET LOSS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2017

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The following table sets forth the computation of net loss per share:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2017		2016		2017		2016
Numerator:
Net loss	$	(3,985,510)	$	(2,102,962)	$	(8,298,772)	$	(878,561)
Less: non-cash income from change in fair value of common stock warrants		-		-		-		2,856,000
Net loss - diluted		(3,985,510)		(2,102,962)		(8,298,772)		(3,734,561)

Denominator:
Weighted average common shares outstanding - basic		10,219,138		7,281,000		9,081,678		6,370,000
Dilutive effect of warrants, net		-		-		-		565,000
Weighted average common shares outstanding - diluted		10,219,138		7,281,000		9,081,678		6,935,000

Net loss per share data:
Basic	$	(0.39)	$	(0.29)	$	(0.91)	$	(0.14)
Diluted	$	(0.39)	$	(0.29)	$	(0.91)	$	(0.54)

Net Loss Per Share

The following securities, rounded to the thousand, were not included in the diluted net loss per share calculation because their effect was anti-dilutive for the periods presented:

	Nine Months Ended
	September 30,
	2017		2016
Common stock options		455,000		432,000
Common stock warrants - equity treatment		6,517,500		5,054,000
Common stock warrants - liability treatment		3,500		6,000
Potentially dilutive securities		6,976,000		5,492,000

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2017

Derivatives and Fair Value [Abstract]

Valuation Methodology

	September 30,			December 31,
	2017			2016
Stock price	$	3.01		$	3.88
Exercise price	$	1.20		$	1.20
Contractual term (years)		0.78			1.15
Volatility (annual)		63	%		100	%
Risk-free rate		1	%		1	%
Dividend yield (per share)		0	%		0	%

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

Financial liabilities measured at fair value on a recurring basis are summarized below and disclosed on the balance sheet under Warrant liability:

Fair value measured at September 30, 2017

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

September 30, 2017

Warrant liability

6,000

Fair value measured at December 31, 2016

Quoted prices in active

Significant other

Significant

markets

observable inputs

unobservable inputs

Fair value at

(Level 1)

(Level 2)

(Level 3)

December 31, 2016

Warrant liability

14,500

Schedule of Changes in Level 3 Liabilities Measured at Fair Value

The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2017:

	Warrant
	Liability
Balance - December 31, 2016	$	14,500
Change in fair value of warrant liability		(8,500)
Balance – September 30, 2017	$	6,000

STOCKHOLDERS’ EQUITY (Tables)

9 Months Ended

Sep. 30, 2017

Stockholders' Equity Note [Abstract]

Summary Of Number Of Price-Reduced and Price-Retained Warrants

Additionally, the exercise prices for certain investors of Series C, Series D and Series F warrants were reduced as follows:

	Number of
	Warrant Shares		Pre-reduced		Post-reduced
Series	Repriced		Price		Price
Series C		313,750	$	6.00	$	4.00
Series D		312,500	$	9.00	$	4.00
Series F		292,500	$	7.20	$	4.00

Valuation Methodology

	Before			After
	Modification			Modification
Exercise price	$	8.32		$	4.04
Contractual term (years)		3.34			3.34
Volatility (annual)		200	%		200	%
Risk-free rate		2	%		2	%
Dividend yield (per share)		0	%		0	%

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

LIQUIDITY AND FINANCIAL CONDITION - Additional Information (Detail) $ in Millions	Sep. 30, 2017 USD ($)
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 7.6

NET LOSS PER SHARE - Computation of income (loss) per share (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Numerator:
Net loss	$ (3,985,510)	$ (2,102,962)	$ (8,298,772)	$ (878,561)
Less: non-cash income from change in fair value of common stock warrants	0	0	0	2,856,000
Net loss - diluted	$ (3,985,510)	$ (2,102,962)	$ (8,298,772)	$ (3,734,561)
Denominator:
Weighted average common shares outstanding - basic	10,219,138	7,281,000	9,081,678	6,370,000
Dilutive effect of warrants, net	0	0	0	565,000
Weighted average common shares outstanding - diluted	10,219,138	7,281,000	9,081,678	6,935,000
Net loss per share data:
Basic	$ (0.39)	$ (0.29)	$ (0.91)	$ (0.14)
Diluted	$ (0.39)	$ (0.29)	$ (0.91)	$ (0.54)

NET LOSS PER SHARE - Potentially Dilutive Securities (Detail) - shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Common stock options	455,000	432,000
Common stock warrants - equity treatment	6,517,500	5,054,000
Common stock warrants - liability treatment	3,500	6,000
Potentially dilutive securities	6,976,000	5,492,000

RESEARCH AGREEMENT OBLIGATIONS - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Gain (Loss) on Extinguishment of Debt	$ 0	$ 0	$ 492,365	$ 0
Crucell Holland BV [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Accrued Liabilities					$ 500,000
Gain (Loss) on Extinguishment of Debt			500,000
Debt Instrument, Increase (Decrease), Net			$ 0

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price	$ 3.01	$ 3.88
Exercise price	$ 1.2	$ 1.20
Contractual term (years)	9 months 11 days	1 year 1 month 24 days
Volatility (annual)	63.00%	100.00%
Risk-free rate	1.00%	1.00%
Dividend yield (per share)	0.00%	0.00%

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Quoted prices in active markets (Level 1)
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	$ 0	$ 0
Significant other observable inputs (Level 2)
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	0	0
Significant other observable inputs (Level 3)
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	6,000	14,500
Fair Value [Member]
Derivatives, Fair Value [Line Items]
Derivative liability - warrants	$ 6,000	$ 14,500

WARRANT LIABILITY AND FAIR VALUE MEASUREMENTS - Conversion Option - Schedule of Changes in Level 3 Liabilities Measured at Fair Value (Detail)	9 Months Ended
	Sep. 30, 2017 USD ($)
Class of Warrant or Right [Line Items]
Balance	$ 14,500
Change in fair value of warrant liability	(8,500)
Balance	$ 6,000

PROMISSORY NOTE - Additional Information (Detail) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Outstanding promissory notes	$ 5,000	$ 5,000
Promissory Notes [Member]
Debt Instrument [Line Items]
Annual interest rate	10.00%

STOCKHOLDERS’ EQUITY - Summary of number of price-reduced and price-retained warrants (Detail) - $ / shares	Sep. 30, 2017	Jun. 23, 2017
Number of Warrant Shares Repriced [Member]
Class of Warrant or Right [Line Items]
Price		$ 15.00
Series C Warrant [Member] \| Number of Warrant Shares Repriced [Member]
Class of Warrant or Right [Line Items]
Number of Warrant Shares	313,750
Series C Warrant [Member] \| Pre-reduced Price [Member]
Class of Warrant or Right [Line Items]
Price	$ 6
Series C Warrant [Member] \| Post-reduced Price [Member]
Class of Warrant or Right [Line Items]
Price	$ 4
Series D Warrant [Member] \| Number of Warrant Shares Repriced [Member]
Class of Warrant or Right [Line Items]
Number of Warrant Shares	312,500
Series D Warrant [Member] \| Pre-reduced Price [Member]
Class of Warrant or Right [Line Items]
Price	$ 9
Series D Warrant [Member] \| Post-reduced Price [Member]
Class of Warrant or Right [Line Items]
Price	$ 4
Series F Warrant [Member] \| Number of Warrant Shares Repriced [Member]
Class of Warrant or Right [Line Items]
Number of Warrant Shares	292,500
Series F Warrant [Member] \| Pre-reduced Price [Member]
Class of Warrant or Right [Line Items]
Price	$ 7.2
Series F Warrant [Member] \| Post-reduced Price [Member]
Class of Warrant or Right [Line Items]
Price	$ 4

STOCKHOLDERS’ EQUITY - Conversion Option - Valuation Methodology (Detail) - Share Purchase Warrants [Member]	9 Months Ended
	Sep. 30, 2017 $ / shares
Weighted Average Inputs Before Modification [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 8.32
Contractual term (years)	3 years 4 months 2 days
Volatility (annual)	200.00%
Risk-free rate	2.00%
Dividend yield (per share)	0.00%
Weighted Average Inputs After Modification [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Exercise price	$ 4.04
Contractual term (years)	3 years 4 months 2 days
Volatility (annual)	200.00%
Risk-free rate	2.00%
Dividend yield (per share)	0.00%

STOCKHOLDERS’ EQUITY - Additional Information (Detail)			1 Months Ended		3 Months Ended		9 Months Ended
STOCKHOLDERS’ EQUITY - Additional Information (Detail)	Sep. 22, 2017 USD ($) shares	Mar. 09, 2017 USD ($) $ / shares shares	Jun. 26, 2017 USD ($) $ / shares $ / Warrant shares	Jun. 23, 2017 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) $ / shares	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2016 USD ($)	Aug. 31, 2016 $ / shares
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation					$ 1,700,000	$ 800,000	$ 2,332,915	$ 1,309,109
Proceeds from Warrant Exercises							619,623	$ 5,483,349
Loss Contingency, Damages Sought, Value			$ 57,000
Adjustments to Additional Paid in Capital, Warrant Issued							$ 0
Class of Warrant or Right,Tranche One [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				$ 15.00
Class of Warrant or Right,Tranche Two [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares				4.50
Subsequent Warrant Issuance [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 3.97
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares			150,357
Liquidated Damages on Aggregate Purchase Price for Registrable Securities			10.00%
Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross \| shares							544,018
Adjustments to Additional Paid in Capital, Warrant Issued							$ 0
Additional Paid-in Capital [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued							$ 622,042
Private Placement [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares			$ 3.97	$ 15.00	$ 3.97		$ 3.97		$ 6.00
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right \| shares				168,000
Legal Fees			$ 800,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares			653,187
Equity Unit Issued Price Per Unit \| $ / Warrant			4.095
Proceeds from Warrant Exercises				$ 700,000
Class of Warrant or Right, Warrant Price \| $ / Warrant			0.125
Proceeds from Issuance of Common Stock			$ 6,200,000
Number Of Units Sold \| shares			1,503,567
Private Placement [Member] \| Class of Warrant or Right,Tranche One [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right \| shares				187,000
Private Placement [Member] \| Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Value, New Issues			$ 1,503,567
Shares Issued, Price Per Share \| $ / shares			$ 3.97
Consulting Agreements [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Fair value of common stock							$ 400,000
Common shares issued \| shares							100,000
Chief Executive Officer, President and Chairman [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross \| shares		12,761
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 55,000
Share Price \| $ / shares		$ 4.31
Chief Operating Officer [Member] \| Unregistered Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation	$ 800,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period \| shares	250,000
Share Based Compensation Arrangement By Share Based Payment Awards, Equity Instruments Other Than Options, Withheld \| shares	70,289
Share Based Compensation Arrangement By Share Based Payment Awards, Equity Instruments Other Than Options, Fair Value Of Instruments Withheld	$ 200,000
President and Chief Operating Officer [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross \| shares		5,220
Stock Issued During Period, Value, Share-based Compensation, Gross		$ 22,500
Share Price \| $ / shares		$ 4.31
Dr. Glynn Wilson [Member] \| Unregistered Common Stock [Member]
Common Stock Capital Shares Reserved For Future Issuance [Line Items]
Share-based Compensation	$ 300,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period \| shares	100,000
Share Based Compensation Arrangement By Share Based Payment Awards, Equity Instruments Other Than Options, Withheld \| shares	27,350
Share Based Compensation Arrangement By Share Based Payment Awards, Equity Instruments Other Than Options, Fair Value Of Instruments Withheld	$ 100,000

STOCK-BASED COMPENSATION - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation	$ 1,700,000	$ 800,000	$ 2,332,915	$ 1,309,109
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 500,000		$ 500,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			7 months 13 days

GRANT INCOME - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Other Nonoperating Income from Grants	$ 183,064	$ 0	$ 183,064	$ 231,200

CONTINGENCIES AND COMMITMENTS - Additional Information (Detail)	Sep. 22, 2017 USD ($)
Chief Operating Officer [Member]
Commitments And Contingencies [Line Items]
Salaries, Wages and Officers' Compensation	$ 362,500
Annual Performance Bonus On Base Salary Percentage Eligible	50.00%
Common Stock to be Received As Grant of Stock Options,Percentage	1.00%
Dr. Glynn Wilson [Member]
Commitments And Contingencies [Line Items]
Salaries, Wages and Officers' Compensation	$ 205,000
Annual Performance Bonus On Base Salary Percentage Eligible	50.00%
Strategic Advisor [Member]
Commitments And Contingencies [Line Items]
Stock Issued During Period, Value, Restricted Stock Award, Gross	$ 300,000